Media

Oncopeptides publishes disclosure document regarding rights issue 

Mahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome

Kivu Bioscience Presents KIVU-305 Preclinical Data at World ADC London 2026 and Advances into Phase 1 Clinical Trial

Positrigo – Launch of the BrainPET Accelerator Program

Oncopeptides carries out a rights issue of approximately SEK 200 million

Oncopeptides publishes year-end report 2025

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

Intervacc Year-end report January – December 2025

European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth